Want to see TCRX full AI Analyst Report?
TCRX Stock Chart & Stats
$1.19
-$0.17(-5.65%)
At close: 4:00 PM EST
$1.19
-$0.17(-5.65%)
Day’s Range― - ―
52-Week Range$0.83 - $2.57
Previous CloseN/A
Volume150.47K
Average Volume (3M)476.93K
Market Cap
$69.27M
Enterprise Value$19.44M
Total Cash (Recent Filing)$128.06M
Total Debt (Recent Filing)$92.54M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Aug 19, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding61,074,230
10 Day Avg. Volume455,904
30 Day Avg. Volume476,927
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.05
Price to Sales (P/S)12.58
P/FCF Ratio-0.93
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue2.13
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$6.00Price Target Upside404.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$7.56M
Bulls Say, Bears Say
Bulls Say
High Gross MarginSustained ~92% gross margin indicates favorable unit economics for the company’s core biologic offerings. As revenue scales, high gross margins support durable profitability potential at the product level and make future commercialization or partner deals more economically attractive.
Pivotal-stage Clinical ProgressRobust Cohort C data and ~90% manufacturing success reflect both clinical signal and operational readiness. Advancing TSC-101 toward a pivotal Phase 3 de-risks late-stage development, strengthens partner and payer credibility, and materially improves long-term commercialization prospects.
Manageable Leverage With Positive EquityA debt-to-equity near 0.62 and positive equity provide solvency cushioning atypical for some early-stage biotechs. This capital structure reduces near-term insolvency risk, giving management more optionality to execute clinical programs before needing immediate distressed financing.
Bears Say
Large Cash BurnConsistently very negative operating and free cash flow (~-$122M to -$125M TTM) creates persistent funding needs. Over time this forces reliance on external capital, increases dilution risk, and limits the firm’s ability to fund multiple programs or accelerate development without new financing.
Modest, Weakening RevenueLow and declining revenue (~$9.1M, -11.5% YoY) signals limited recurring commercial traction and reliance on one-off collaboration or grant income. Structurally weak top-line inflows exacerbate funding pressure and make sustainable operations dependent on continued external financing or successful asset monetization.
Dilution Risk From Equity Decline And Authorized Share ExpansionBoard-approved doubling of authorized shares, combined with equity falling from ~$241M in 2024 to ~$96.9M, materially expands the company’s capacity to issue stock. This structural change raises the probability of meaningful dilution as management likely needs equity to fund ongoing cash burn and late-stage trials.
TScan Therapeutics News
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $0.82 and its highest was $2.57 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $69.27M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 39 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on May 06, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.018.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 61,074,230 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went up 3.306%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (404.20% Upside)
$6.00 (404.20% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.14%
12-Months-Change
Fundamentals
Return on Equity
-91.94%
Trailing 12-Months
Asset Growth
-39.29%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$6.00
▲(404.20% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
17.47% Insiders
5.44% Mutual Funds
32.09% Other Institutional Investors
41.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---